Zhiqiang Shi

Clinical Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy for Triple‐Negative Breast Cancer and Tumor Immune Microenvironment Analysis: A Prospective‐Retrospective Cohort Study

ABSTRACT The impact of immune checkpoint inhibitors combined with neoadjuvant chemotherapy (NAC) on surgical outcomes and immune remodeling remains underexplored. To investigate the efficacy and tumor immune microenvironment (TIME) changes of camrelizumab plus NAC for triple‐nega...